Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung(Yonsei University), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Jean‐Pierre Delord, Maya Gottfried(Meir Medical Center), Wilson H. Miller(Jewish General Hospital), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Alona Zer(Rambam Health Care Campus), Shadia I. Jalal(Indiana University Health), Aurélien Marabelle(Institut Gustave Roussy), Bo Gao(Sun Yat-sen University), José A. López-Martín(Research Institute Hospital 12 de Octubre), Lei Xu(U.S. National Science Foundation), Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susan Zeigenfuss, Stephen Chuan-Hao Kao(Chris O’Brien Lifehouse), Willeke Ros(The Netherlands Cancer Institute)
Cited by 208
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k